RT Journal Article
T1 Role of Age and Hematopoietic Cell Transplantation-Specific Comorbidity Index in Myelodysplastic Patients Undergoing an Allotransplant: A Retrospective Study from the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation.
A1 Carré, Martin
A1 Porcher, Raphaël
A1 Finke, Jürgen
A1 Ehninger, Gerhard
A1 Koster, Linda
A1 Beelen, Dietrich
A1 Ganser, Arnold
A1 Volin, Liisa
A1 Lozano, Sara
A1 Friis, Lone
A1 Michallet, Mauricette
A1 Tischer, Johanna
A1 Olavarria, Eduardo
A1 Cascon, Maria Jesús Pascual
A1 Iacobelli, Simona
A1 Koc, Yener
A1 Jindra, Pavel
A1 Arat, Mutlu
A1 de Witte, Theo
A1 Yakoub Agha, Ibrahim
A1 Kröger, Nicolaus
A1 Robin, Marie
K1 Age
K1 Comorbidities
K1 Myelodysplastic syndromes
K1 Nonrelapse mortality
K1 Transplantation
AB Allogeneic hematopoietic stem cell transplantation (HSCT) remains the only potentially curative option for myelodysplastic syndromes (MDSs) but is severely limited by nonrelapse mortality (NRM), especially in this mostly older population. Comorbidity assessment is crucial to predict NRM and often assessed with the Hematopoietic Cell Transplantation-Specific Comorbidity Index (HCT-CI). Moreover, the impact of age on NRM still remains a matter of debate. In recent years, the age at which transplants are made has been progressively increasing, and patients with comorbidities have become more common. Extricating the respective roles of age and comorbidities in toxic mortality is all the more important. This study by the European Group for Blood and Marrow Transplantation registry included 1245 adult patients who underwent a first allogeneic stem cell transplantation for MDSs between 2003 and 2014. Overall, 4-year NRM and overall survival were 32% and 47%, respectively. When considered as continuous predictors, HCT-CI score and age were associated with an increased hazard ratio (HR) for NRM. In multivariate analysis, age band (HR, 1.13; 95% CI, 1.02 to 1.25; P= .016), HCT-CI ≥3 (HR, 1.34; 95% CI, 1.04 to 1.73; P = .022), and Karnofsky Performance Status ≤80 (HR, 2.03; 95% CI, 1.52 to 2.73; P
YR 2019
FD 2019-10-21
LK http://hdl.handle.net/10668/15278
UL http://hdl.handle.net/10668/15278
LA en
DS RISalud
RD Apr 12, 2025